Hi Reg and thanks.
Check this link out for further details regarding the MesenCure study (adipose derived MSCs for COVID-ARDS):
https://www.jpost.com/health-and-wellness/coronavirus/israeli-drug-for-severe-covid-reduces-death-by-70-percent-phase-2-trial-686879.
Another successful study in treating severe COVID-ARDS using MSCs (this study enrolled patients with diffuse pneumonia that was affecting the patients oxygen saturation). Note this phase II clinical trial used up to three (3) does during the patients' hospital stay.
Maybe SI could also investigate multiple dosages for the over 65's in any upcoming trial?
Note this study was discussed previously in the Cell Therapy News/Articles thread (on 25 Nov 2021) if you want to research further.
Hope this helps.
Growing doubt on COVID-19 Application, page-1969
-
- There are more pages in this discussion • 2,766 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 64563 | 93.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 204239 | 3 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |